Certainly, further research is needed in order to better unravel the role of the MTHFD1 1958 A>G variant in ovarian cancer risk, as this protein may be a potential therapeutic target for future ovarian cancer therapies. This evidence concerns the gene MTHFD1 and ovarian carcinoma.